▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / MYGN

MYGN — MYRIAD GENETICS INC

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 899923 ·
Last close
$5.83
Market Cap
$550.63M
52W High
$6.26
52W Low
$3.53
ADV30
1,761,494
Next earnings
—
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 200,400,000 137,600,000 -25,300,000 -34,100,000 673,700,000 124,400,000 336,300,000
Dec 2025 209,800,000 146,800,000 -3,000,000 -7,900,000 706,600,000 149,600,000 338,600,000
Sep 2025 205,700,000 143,800,000 -23,300,000 -27,400,000 728,100,000 145,400,000 355,300,000
Jun 2025 213,100,000 151,800,000 -12,500,000 -330,500,000 677,300,000 74,400,000 289,200,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,400,000
Investing CF
$-25,600,000
Financing CF
$47,600,000
CapEx
$-25,600,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.30
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,156,800,000
Inventory
$27,900,000
Receivables
$123,800,000
ST Investments
$0
EBIT TTM
$-386,000,000
Pretax Income TTM
$-399,800,000
Interest Exp TTM
$13,800,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$557,000,000
EBITDA
$-111,900,000
Free Cash Flow
$-46,062,500
Enterprise Value
$425,434,080
Total Cash
$150,700,000
Total Debt
$0
Shares Out
94,448,210
Trailing EPS
$-4.31
Book Value
$3.57
ROE
-23.5%
ROA
-7.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 824,500,000 -67,800,000 -365,900,000 706,600,000 338,600,000 — 1,800,000
Dec 2024 837,600,000 -88,000,000 -127,300,000 1,027,600,000 326,500,000 — -8,700,000
Dec 2023 753,200,000 -144,600,000 -263,300,000 1,146,500,000 363,300,000 — -110,900,000
Dec 2022 678,400,000 -123,700,000 -112,000,000 1,198,700,000 312,900,000 — -106,300,000

TTM Snapshot

Revenues TTM
$728,900,000
NetIncome TTM
$-93,900,000
OpCashFlow TTM
$0
Assets (Latest)
$1,027,600,000
Forward EPS
$0.15

Peers — same industry

TickerNameMarket CapLastDaily %
NRC NRC HEALTH $487.92M $21.65 —
ACHV ACHIEVE LIFE SCIENCES, INC. $627.25M $6.11 —
NNNN Anbio Biotechnology $412.14M $9.39 —
OABI OmniAb, Inc. $331.99M $2.29 —
TKNO Alpha Teknova, Inc. $287.37M $5.36 —

News headlines (Yahoo Finance, 1h cache)

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
2026-07-02 13:05 · Yahoo
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
2026-07-01 09:37 · Yahoo
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
2026-06-30 15:47 · Yahoo
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
2026-06-29 10:46 · Yahoo
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
2026-06-24 19:12 · Yahoo
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
2026-06-23 13:05 · Yahoo
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
2026-06-09 14:01 · Yahoo
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
2026-06-05 13:12 · Yahoo
3 High-Flying Stocks We’re Skeptical Of
2026-06-04 20:45 · Yahoo
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
2026-06-04 15:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →